FSD Pharma Files 6-K, Expands Investigative Pipeline
Ticker: QNTM · Form: 6-K · Filed: Apr 17, 2024 · CIK: 1771885
| Field | Detail |
|---|---|
| Company | Fsd Pharma Inc. (QNTM) |
| Form Type | 6-K |
| Filed Date | Apr 17, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, pipeline-expansion, R&D
TL;DR
FSD Pharma filed a 6-K on 4/17, hinting at pipeline expansion. Keep an eye on R&D news.
AI Summary
FSD Pharma Inc. filed a Form 6-K on April 17, 2024, to report on its activities for April 2024. The filing includes a press release titled "FSD Pharma Expands Investigative Pip" which suggests the company is advancing its research and development efforts. Nathan Coyle, Chief Financial Officer, signed the report.
Why It Matters
This filing indicates ongoing operational activities and potential pipeline expansion for FSD Pharma, which could impact its future drug development and market position.
Risk Assessment
Risk Level: medium — Form 6-K filings often contain updates that can be material, but without specific details on the 'investigative pip' expansion, the immediate impact and associated risks are unclear.
Key Players & Entities
- FSD Pharma Inc. (company) — Registrant
- Nathan Coyle (person) — Chief Financial Officer
- April 17, 2024 (date) — Filing Date
- 001-39152 (other) — Commission File Number
FAQ
What specific area of its investigative pipeline is FSD Pharma expanding?
The filing mentions "FSD Pharma Expands Investigative Pip" in Exhibit 99.1, but does not specify the exact area of expansion.
When was this Form 6-K filed?
This Form 6-K was filed on April 17, 2024.
Who signed the Form 6-K on behalf of FSD Pharma Inc.?
Nathan Coyle, Chief Financial Officer, signed the Form 6-K.
What is FSD Pharma Inc.'s principal executive office address?
FSD Pharma Inc.'s principal executive office is located at 199 Bay St., Suite 4000 Toronto, Ontario M5L 1A9, Canada.
Does FSD Pharma Inc. file annual reports under Form 20-F or 40-F?
FSD Pharma Inc. indicated it files annual reports under Form 20-F.
Filing Stats: 146 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-04-17 08:01:43
Filing Documents
- fsd_6k.htm (6-K) — 9KB
- fsd_ex991.htm (EX-99.1) — 14KB
- fsd_ex991img2.jpg (GRAPHIC) — 6KB
- 0001654954-24-004708.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. FSD Pharma Inc. (Registrant) Date: April 17, 2024 By: /s/ Nathan Coyle Nathan Coyle, Chief Financial Officer 2 EXHIBIT INDEX Exhibit Description 99.1 Press Release 3